NCT06205381View on ClinicalTrials.gov

Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

February 8, 2025

Study Completion Date

February 8, 2025

Conditions
Healthy Participants
Interventions
DRUG

AV078

Oral solution containing active ingredient, AV078

DRUG

Placebo

Oral solution with no active ingredients

DRUG

Itraconazole

Once daily oral dose of 200 mg itraconazole administered for 9 days

DRUG

Midazolam

2.5 mg midazolam administered orally on day 1 and day 18

DRUG

Fexofenadine

120 mg fexofenadine administered orally on day 1 and day 18

Trial Locations (2)

3220

Nucleus Network Pty Ltd, Melbourne

4006

Q-Pharm, Herston

Sponsors
All Listed Sponsors
lead

Aeovian Pharmaceuticals, Inc.

INDUSTRY

NCT06205381 - Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers | Biotech Hunter | Biotech Hunter